

# ROTER

In cases of dyspepsia with or without a radiologically proven ulcer Roter will normally provide prompt symptomatic relief and lead to rapid healing of the lesion. The reputation of Roter is world wide. It is a complete treatment in itself and requires no additional antispasmodics or anticholinergics.




**FORMULA:** Each Roter tablet contains: Bismuth Subnitrate Roter (350 mg.), Magnesium Carbonate (400 mg.), Sodium Bicarbonate (200 mg.) and Cortex Rhamni Frangulae (25 mg.).

**PACKINGS OF ROTER TABLETS:** Tins of 40 and 120, also dispensing sizes, 360 and 720 (P.T. exempt).

## ROTER IN PEPTIC ULCER

# AMINOSOL 10% + INTRALIPID (FAT EMULSION)



**FOR COMPLETE PARENTERAL NUTRITION**

*... without risk of Thrombophlebitis*



*literature and suggested regimes on request*

**PAINES & BYRNE LTD., GREENFORD, MIDDLESEX**  
*pre-eminent in Parenteral Nutrition*

# Lomotil does just one thing it stops diarrhoea

. . . patients began to feel more comfortable . . . after approximately one hour.'

Hock, C.W. (1961)  
*J.med.Ass.Ga.*, 50,485

Most diarrhoeas are non-specific in origin. Lomotil (brand of diphenoxylate hydrochloride with atropine sulphate) provides the rapid, symptomatic control needed in such cases.

In diarrhoea of specific origin, Lomotil conserves electrolytes and prevents dehydration while antibacterial treatment takes effect.

Lomotil curbs the intestinal hypermotility characteristic of diarrhoea. It is effective in virtually all types of diarrhoea — acute, chronic or recurrent.

*Lomotil is a registered trade mark*

THE RAPID-ACTING ANTI-DIARRHOEAL

# Lomotil

Searle

# The success of BIOGASTRONE (carbenoxolone sodium) in gastric ulcer


## further proof in 1965



**“It is the only drug therapy for gastric ulcer which has been demonstrated conclusively to accelerate healing,**

**which can be achieved with patients remaining up and about, often at work, and with minimum change in diet”**

from editorial synopsis: GUT (1965) 6:19



In 1959, the first clinical trial of Biogastrone\* was begun in patients with gastric ulcer. The results indicated that Biogastrone significantly reduced the size of ulcer niche.

**“It is suggested that Biogastrone promotes the healing of gastric ulcers.”**

Lancet (1962) ii: 793

Now, in a further trial, the same author proves beyond any doubt that Biogastrone is successful in assisting gastric ulcers to heal. The average degree of healing was similar in both trials—72 and 78% in the Biogastrone groups and 35 and 39% for the control.

**“It is concluded that carbenoxolone sodium [Biogastrone] facilitates the healing of gastric ulcers.”**

Gut (1965) 6: 19

More detailed information from  
**Berk Pharmaceuticals Limited, Catteshall Lane  
Godalming, Surrey.**

\* trade mark BR 3775/J817

# OVERWRAP PRESENTATION

Now, Ethicon offers you a new secure packaging choice—a sterile pack system that delivers full future packs to you dry in a sterile overwrap. This eliminates a storage problem. There are none to open. Overwrap packs break easily and evenly over time. So the future pack is protected against all future contamination.

**ETHICON LIMITED**


Wallingford, England, OX10 9BA

**ETHICON** selling new products

dry sterile pack

just peel back and open





**2 TABLETS TWICE A DAY—  
PROVEN MAINTENANCE THERAPY**

**In Ulcerative Colitis**

---

available as a 0.5 g. tablet, either plain or enteric coated

**FIRST DEMONSTRATION . . . RESULTS SIGNIFICANT**

*"This is the first demonstration in a formal trial that any treatment reduces the relapse-rate in ulcerative colitis, 24 out of 34 patients taking 2 g. of sulphasalazine daily remained free of symptoms for a year. This result is significantly different from that obtained in a comparable group of patients who received a placebo."*

**PREFERABLE TO SYSTEMIC CORTICOSTEROIDS**

*"We have shown that sulphasalazine, 0.5 g. four times daily, is often effective in maintaining remission . . . and it therefore appears preferable to systemic corticosteroid drugs for this purpose."*

**REMISSION FOR ONE YEAR**

*"24 patients remained in symptomatic remission for a year while taking 2 g. of sulphasalazine daily, whereas only 8 remained symptom-free in the placebo group."*

**NORMAL MUCOSA**

*"2 of the 24 patients who remained symptom-free for a year while on sulphasalazine had a haemorrhagic mucosa at the end of the trial. The remaining 22 patients had a non-haemorrhagic mucosa which in many cases appeared normal."*

**MINIMAL SIDE EFFECTS**

*"In the present trial, using a dose of 2 g. daily, only 3 patients out of 34 had to discontinue treatment because of side-effects."*

**WHITE CELL COUNT**

*"In the patients treated with sulphasalazine there was no difference in the haemoglobin level before and after treatment; but the mean white-cell count was lower after six months or a year than at the start of treatment, though in no patient was it less than 4500 per c.mm."*

The Lancet Jan 23rd 1965 • Vol I • Pages 185-188

# SALAZOPYRIN


 **PHARMACIA**  
(GREAT BRITAIN) LTD

Literature and further information are supplied on request  
**SINCLAIR HOUSE • THE AVENUE • WEST EALING • LONDON W13**


Distributed by Martindale Samoore Ltd • 60-61 Welbeck St • London W1



Strength in hand



with London Hospital Sutures




**Strong, sure, supple — packaged for speed and safety.  
Available in a full range of catgut and non-absorbable  
materials with or without eyeless needles**



**London Hospital (Ligature Department) Ltd • Faringdon Avenue • Harold Hill • Romford • Essex  
Telephone Ingrebourne 41101-4 • Telegrams "Ultratan Romford"**





## LONGER-LASTING DRIP THERAPY

Gastrils—first ever antacid pastilles. Gastrils do not break up in the mouth like tablets; they dissolve slowly and smoothly, so give sustained drip therapy for the treatment of peptic ulcer.

Gastrils contain a co-dried gel of aluminium hydroxide and magnesium carbonate, a buffer antacid comparable in activity to freshly prepared liquid aluminium hydroxide gel. Gastrils rapidly buffer gastric pH to an optimum level, and keep it there, without risk of acid rebound.

To relieve the tedium of constant antacid therapy, every Gastrils prescription is dispensed in equal quantities of two delicious flavours—mint and fruit. Few antacids are as effective as Gastrils—none is as good to take!

# GASTRILS

## ANTACID PASTILLES

**INDICATIONS** Hyperacidity, peptic ulcer, gastritis, heartburn, oesophagitis and hiatus hernia.

**FORMULA** Each pastille contains 500 mg. co-dried gel of aluminium hydroxide and magnesium carbonate.


**BASIC N.H.S. COST** 24 individually wrapped Gastrils in carton 3/-.  
24 individually wrapped Gastrils from dispensing pack: 2/6½d. Gastrils are prescribable on form E.C.10

*'Gastrils' is a registered trade mark of T. J. Smith & Nephew Ltd.*



**Smith & Nephew  
Pharmaceuticals Limited**

WELWYN GARDEN CITY · HERTFORDSHIRE · ENGLAND



a masked disease

**Pancreatitis** may be difficult to differentiate from a coronary thrombosis, perforated peptic ulcer, a dissecting aneurysm of the aorta or acute cholecystitis, but when the diagnosis is established, TRASYLOL the proteinase inactivator is indicated.

TRASYLOL specifically inhibits the proteolytic enzymes of the pancreas, and administered in adequate dosage arrests the autodigestive processes.

**A recent analysis of all cases of pancreatitis, those treated with TRASYLOL showed a reduction in mortality from 22% to 9%.**

TRASYLOL is therefore indicated in the treatment of acute pancreatitis, pancreatic fistulae, and pancreatitis accompanying disorders of the gall bladder and bile ducts.

# TRASYLOL<sup>®</sup>

Proteinase Inactivator



<sup>®</sup> Registered trade mark of **BAYER LEVERKUSEN GERMANY**  
U.K. Subsidiary **FBA PHARMACEUTICALS LTD**, Haywards Heath, Sussex

# don't use Merbentyl to inhibit gastric secretion

## because

Merbentyl is not an antisecretory drug. Do use it to control gastrointestinal spasm because here Merbentyl is a remarkably effective antispasmodic. Moreover, Merbentyl is so selective that its use is rarely followed by side effects commonly seen with other drugs used for this purpose. It can even be administered to patients with chronic simple glaucoma or prostatic hypertrophy.

Merbentyl (dicyclomine hydrochloride B.P.C.) was first described in 1947, and has been widely used clinically to control gastrointestinal spasm and hypermotility in many countries for over 12 years. It acts both on the neuroreceptor sites innervated by post-ganglionic parasympathetic fibres, and directly on smooth muscle tissue.

### Indications

- 1 Primary functional disorders of the gastro-intestinal tract: spastic colon, pylorospasm, post-cholecystectomy syndrome.
- 2 Adjunctive therapy in organic disorders, e.g. ulcerative colitis, diverticulitis.
- 3 Infant colic (here the drug is regarded as specific therapy).

**Low NHS. cost** An average week's treatment—2/8d.

**Merbentyl tablets** each tablet contains 10mg. dicyclomine hydrochloride B.P.C. Recommended adult dosage, 2 t.d.s.

*Also available with phenobarbitone and as Merbentyl Syrup.*

Full clinical information available on request.



Merrell-National (Laboratories) Limited, 20 Savile Row, London, W.1.


---

# **\*Prodexin**<sub>regd.</sub>

---

continuous drip control of ulcer  
by tablet

---



**PRODEXIN** tablets give all the benefits of continuous intragastric drip therapy<sup>1</sup> without any of its disadvantages.

The slow suck down tablets are specially formulated to give prolonged antacid buffer effect, unaffected by stomach emptying rate.<sup>2</sup>

Immediate relief of pain is achieved by rapidly raising pH to 2 neutralising excess acid and controlling the acid secretion by slowly building up the pH to a desirable level of pH3.5 and pH4.5

#### **DOSAGE:**

For continuous therapeutic effect one tablet at a time should be sucked slowly.  
For peptic ulcer one or more tablets an hour.

#### **References:**

1. Practitioner (1954), 173, 46.
2. Post Grad. med. J. (1960) 36, 722.

\*Aluminium Glycinate 0.9G.  
Light Magnesium Carbonate B.P. 0.1G.

**PRODEXIN** is a product of British research at

**Beecham Research Laboratories**



# VELACTIN

WANDER

A readily assimilated milk substitute  
of vegetable origin for Milk Allergies



M441

Velactin contains no gluten or lactose. The biological value of the soya protein has been improved by the addition of DL-Methionine to make it equivalent to that of first-class animal protein.

*Literature gladly sent on request*

A. Wander Limited,  
42 Upper Grosvenor Street,  
London W.1.

**Indications:** Allergy or intolerance to human or cow's milk.<sup>1</sup> As basic feeding pending identification of specific food allergens.<sup>1</sup> Galactosaemia.<sup>2,3</sup> Gluten enteropathy. Velactin may also be tried in cases of undetermined metabolic or non-specific intolerance.

**References:** (1) *Nutritio et Dieta* 1961; **3**, 89.  
(2) *Lancet* 1959, **2** 849; 1960 **1**, 336.  
(3) *Ugeskrift f. Laeger* 1960, **122**, 1229.

**Presentation:** Tin containing 9 oz. net.

## ANTIBIOTICS AND THE INTESTINAL FLORA

Treatment with broad spectrum antibiotics suppresses the normal flora, which may be replaced by abnormal resistant organisms causing diarrhoea.

This change can be prevented or reversed by the implantation of *Lactobacillus acidophilus* which has been rendered antibiotic-resistant, and is thus able to multiply freely under these abnormal conditions. The products of growth of this organism are inimical to that of many other bacteria<sup>1,2</sup> and thus contribute to its rapid preponderance over other species.

Oral treatment with antibiotic-resistant *L. acidophilus* in the form of ENPAC has been shown to eliminate *Candida* from the faeces of infants with antibiotic-induced diarrhoea, with relief of symptoms succeeded by rapid gain in weight<sup>3,4</sup> and greatly to reduce the numbers of staphylococci in the faeces of patients treated with tetracyclines.<sup>5</sup>

<sup>1</sup> (1958) *Ann. Inst. Pasteur* **95**, 194.

<sup>2</sup> (1959) *J. Bact.* **78**, 477.

<sup>3</sup> (1957) *Klin. Wschr.* **35**, 198.

<sup>4</sup> (1959) *Medizinische* **7**, 296.

<sup>5</sup> (1957) *Lancet* (i), 899.



# ENPAC

## LACTOBACILLUS ACIDOPHILUS PREPARATION

Samples and literature will be sent to the medical profession on request to:—

**APLIN and BARRETT LIMITED · BIOLOGICALS DIVISION · TROWBRIDGE · WILTS**

## SECOND SYMPOSIUM OF THE FACULTY OF MEDICINE UNIVERSITY OF ALBERTA

### “Gastric Secretion — Mechanisms and Control”

An international symposium to be held on September 13, 14 and 15, 1965, at the University of Alberta, Edmonton, Canada.

The following authorities will participate:

Andersson, Dr. Sven  
Blair, Dr. E. L.  
Card, Dr. W. I.  
Clarke, Dr. J. S.  
Code, Dr. C. F.  
Davies, Dr. R. E.  
Dragstedt, Dr. L. R.  
Elliott, Dr. Dan W.  
Ellison, Dr. E. H.  
Glass, Dr. G. B. J.  
Gregory, Dr. R. E.  
Grossman, Dr. M. I.  
Hollander, Dr. F.  
Irvine, Prof. W. T.

Stockholm  
Newcastle upon Tyne  
Edinburgh  
Albuquerque  
Rochester  
Philadelphia  
Gainesville, Fla.  
Pittsburgh  
Milwaukee  
New York  
Liverpool  
Los Angeles  
New York  
London

Ito, Dr. S.  
Jeffries, Dr. Graham H.  
Jordan, Dr. Paul H.  
Leonard, Dr. A. S.  
Menguy, Dr. René  
Murray, Prof. J. G.  
Olbe, Dr. Lars  
Rasanen, Dr. Toimi  
Rudick, Dr. J.  
Schofield, Dr. B.  
Sircus, Dr. W.  
Teir, Dr. Harold  
Thompson, Dr. J. C.  
Webster, Dr. D. R.

Boston  
New York  
Houston  
Minneapolis  
Lexington  
London  
Gothenburg  
Helsinki  
Seattle  
Newcastle upon Tyne  
Edinburgh  
Helsinki  
Torrance, California  
Montreal

**Registration Fee: \$50.00**

Further details may be obtained from Chairman of Symposium, Room C148, University Hospital, Edmonton, Alberta, Canada.

# BRITISH MEDICAL JOURNAL



A comprehensive general medical journal. Essential for every medical man or student who wishes to keep informed of research in medical science, of trends in clinical medicine and of professional activities.

*Weekly. Annual Subscription, United Kingdom, Irish Republic, £9 9s.; Abroad £5 5s. (\$15.00).*

## **and its associated specialist journals**

### **BRITISH JOURNAL OF OPHTHALMOLOGY**

Designed for the clinician and research worker and includes original articles, case notes, information on new appliances, book reviews.

*Monthly. Annual Subscription, Inland £6 6s.; Overseas £7 (\$20.00). (Combined subscription for the two Ophthalmic journals, Inland £11 11s.; Overseas £13 (\$37.00)).*

### **OPHTHALMIC LITERATURE**

Abstracts of articles on the wide field of ophthalmology published throughout the world. Each volume contains some 5,000 abstracts—covering one year.

*Six issues a year plus index. Annual Subscription, Inland £6 6s.; Overseas £7 (\$20.00). (For combined subscriptions see above.)*

### **JOURNAL OF CLINICAL PATHOLOGY**

Original and specially commissioned articles on each branch of pathology, with prominence given to its clinical application. Technical methods, notes on new or improved apparatus, book reviews.

*Annual Subscription (six issues), Inland £4 4s.; Overseas £4 15s. (\$14.00).*

### **BRITISH HEART JOURNAL**

Original work on the heart and circulation—anatomical, physiological and pathological.

*Annual Subscription (six issues), Inland £4 4s.; Overseas £4 15s. (\$14.00).*

### **ARCHIVES OF DISEASE IN CHILDHOOD**

Devoted to child health and disease, with emphasis on clinical paediatrics. Original articles by paediatricians and other specialists.

*Annual Subscription (six issues), Inland £4 4s.; Overseas £4 15s. (\$14.00).*

### **BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY**

Reports on original work in all branches of the subject, including experimental chemotherapy. Biochemical and pathological studies.

*Annual Subscription (six issues), Inland £10 10s.; Overseas £11 (\$32.00).*

### **JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY**

Original articles on current research, throwing light on practice in neurology, neurosurgery and psychiatry.

*Annual Subscription (six issues), Inland £4 4s.; Overseas £4 15s. (\$14.00).*

### **ANNALS OF THE RHEUMATIC DISEASES**

Original articles by authorities in the U.K., U.S.A. and elsewhere on every manifestation of the rheumatic diseases. Summaries in English, French and Spanish.

*Annual Subscription (six issues), Inland £4 4s.; Overseas £4 15s. (\$14.00).*

### **THORAX**

Original work on the anatomy, physiology and pathology of the chest and heart. Descriptions of techniques and apparatus used in modern cardiac surgery.

*Annual Subscription (six issues), Inland £4 4s.; Overseas £4 15s. (\$14.00).*

### **GUT**

Journal of the British Society of Gastroenterology. A journal for physicians, surgeons, radiologists, and pathologists, carrying authoritative articles on all aspects of gastroenterology.

*Annual Subscription (six issues), Inland £4 4s.; Overseas £4 15s. (\$14.00).*

### **JOURNAL OF MEDICAL GENETICS**

A new journal publishing articles on clinical, statistical, pathological, cytological and biochemical aspects of medical genetics.

*Quarterly. Annual Subscription, Inland £3 3s.; Overseas £3 10s. (\$10.00).*

### **BRITISH JOURNAL OF VENEREAL DISEASES**

Designed to disseminate, exchange and increase knowledge among consultants, practitioners, research workers, teachers and others concerned with the problem of venereal diseases.

*Quarterly. Annual Subscription, Inland £3 3s.; Overseas £3 10s. (\$10.00).*

### **BRITISH JOURNAL OF INDUSTRIAL MEDICINE**

Authoritative papers on all aspects of occupational medicine, e.g., the pneumoconioses, occupational cancers, industrial toxicology and psychology.

*Quarterly. Annual Subscription, Inland £3 3s.; Overseas £3 10s. (\$10.00).*

### **BRITISH JOURNAL OF PREVENTIVE AND SOCIAL MEDICINE**

Original work in the field, the emphasis on epidemiological methods and medical research.

*Quarterly. Annual Subscription, Inland £3 3s.; Overseas £3 10s. (\$10.00).*

### **MEDICAL AND BIOLOGICAL ILLUSTRATION**

Illustration and its application to the requirements of the medical and biological sciences.

*Quarterly. Annual Subscription, Inland £3 3s.; Overseas £3 10s. (\$10.00).*

### **ABSTRACTS OF WORLD MEDICINE**

Critical abstracts of important articles appearing in medical periodicals in every part of the world. Accent on what is new.

*Monthly. Annual Subscription, Inland and Overseas £6 6s. (\$18.00).*


*Write to The Subscription Manager, BRITISH MEDICAL JOURNAL,  
B.M.A. House, Tavistock Square, London W.C.1  
or order through any leading subscription agent or bookseller  
(All dollar rates quoted refer to the U.S. dollar)*

# 'ALUHYDE'

for prompt, safe symptomatic medication in  
hyperchlorhydria and peptic ulcer

'ALUHYDE' tablets present a new combination with these advantages...


'ALUHYDE' effects safe, reliable, non-systemic neutralization by means of two of the most preferred modern antacid adsorbents...



'ALUHYDE' permits of quick mental sedative effect by its inclusion of a barbiturate recognized for minimal cumulative potential...



'ALUHYDE' provides antispasmodic action through its content of an agent long known for its favourable influence against hypermotility...



## Formula—

Each tablet:	Dried Aluminium Hydroxide Gel. B.P.C.	-	3.75 gr.
	Magnesium trisilicate B.P.	-	3.75 gr.
	Quinalbarbitone sodium B.P.	-	0.50 gr.
	Tinct. Belladonnæ B.P.	-	3 m.

Packings—Regular packs of 50 ; bottles of 500 (dispensing)

*Samples available on personally signed request  
of qualified physicians only*

**MULTIPAX CHEMICALS LTD**

121 NORWOOD ROAD, LONDON, S.E.24

Phone : TULse Hill 3276



IAS3